← Leaderboards
Douglas B Johnson
Vanderbilt University Medical Center
$4,571,867
Attributed
$8,014,374
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,014,374 · 6
By mechanism
R01$5,900,814 · 2
T32$984,201 · 1
K23$756,000 · 1
P30$373,359 · 2
Top collaborators
- Justin M Balko5 shared
- Javid J Moslehi5 shared
- Debra L Friedman3 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Madan Jagasia$248,906
- Krystle A. Kuhs$3,664,442
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightMalignant NeoplasmsImmune Checkpoint InhibitorResponseCellsToxic EffectT-LymphocytePreventAffectMultidisciplinaryCancer TherapyImmunotherapyImmuneMolecularInternationalOncologyOrganLongitudinal StudiesGeneticCheckpoint TherapyMyocarditisCtla4 GeneMediatingAutopsy
Grant awards (21)
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$615,145
R01 · FY2025 · HL
VOLT (Vanderbilt Oncology Training Program)$303,759
T32 · FY2025 · CA · contact PI
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$606,001
R01 · FY2024 · HL
VOLT (Vanderbilt Oncology Training Program)$322,587
T32 · FY2024 · CA · contact PI
Translational Research and Interventional Oncology Research Program$124,453
P30 · FY2024 · CA · contact PI
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$618,167
R01 · FY2023 · HL
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$511,114
R01 · FY2023 · CA
VOLT (Vanderbilt Oncology Training Program)$357,855
T32 · FY2023 · CA · contact PI
Translational Research and Interventional Oncology Research Program$124,453
P30 · FY2023 · CA · contact PI
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$631,885
R01 · FY2022 · HL
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$507,066
R01 · FY2022 · CA
Translational Research and Interventional Oncology Research Program$124,453
P30 · FY2022 · CA · contact PI
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$833,492
R01 · FY2021 · HL
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$517,415
R01 · FY2021 · CA
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$521,546
R01 · FY2020 · CA
Predicting and profiling long-term survival after immune checkpoint inhibition$151,200
K23 · FY2020 · CA · contact PI
(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition$538,983
R01 · FY2019 · CA
Predicting and profiling long-term survival after immune checkpoint inhibition$151,200
K23 · FY2019 · CA · contact PI
Predicting and profiling long-term survival after immune checkpoint inhibition$151,200
K23 · FY2018 · CA · contact PI
Predicting and profiling long-term survival after immune checkpoint inhibition$151,200
K23 · FY2017 · CA · contact PI
Predicting and profiling long-term survival after immune checkpoint inhibition$151,200
K23 · FY2016 · CA · contact PI